Table 1.
Clinical characteristics, serum levels of cardiac biomarkers, and the main echocardiographic parameters of the 55 CA patients, grouped according to the presence or absence of aortic valve stenosis
| Patients without AS (n = 50) | Patients with AS (n = 5) | p-value | |
|---|---|---|---|
| Clinical data | |||
| Age (years) | 63.5 (58–73) | 69 (68–82) | p = 0.055 |
| Male (n, %) | 26 (52%) | 3 (60%) | p = 0.553 |
| wtTTR CA (n, %) | 2 (4%) | 1 (20%) | p = 0.391 |
| mTTR CA (n, %) | 6 (12%) | 0 (0%) | p = 0.485 |
| AL amyloidosis (n, %) | 40 (80%) | 4 (80%) | p = 0.741 |
| AA amyloidosis (n, %) | 1 (2%) | 0 (0%) | p = 0.909 |
| NYHA III-IV stage (n, %) | 32 (64%) | 5 (100%) | p = 0.278 |
| Atrial fibrillation (n, %) | 11 (22%) | 1 (20%) | p = 0.312 |
| Laboratory data | |||
| B-type natriuretic peptide (pg/ml) | 606 (234–1240) | 341 (77–657) | p = 0.303 |
| Troponin T (ng/L) | 66 (39–104) | 134 (47–215) | p = 0.464 |
| Echocardiography | |||
| Left ventricular ejection fraction (%) | 56 (43–63) | 59 (51–60) | p = 0.823 |
| Septal wall thickness (mm) | 16 (13–18) | 17 (13–20) | p = 0.578 |
| Inferior wall thickness (mm) | 15 (13–17) | 15 (13–16) | p = 0.780 |
| Left ventricular end diastolic diameter (mm) | 42 (36–45) | 41 (37–42) | p = 0.776 |
| E/e’ (Average of lateral and septal e’) | 20.6 (16–24) | 18.1 (16.9–20.6) | p = 0.241 |
| Lateral S′ | 5.5 (4–7) | 6.25 (4,25–8.3) | p = 0.588 |
AS aortic valve stenosis; wtTTR wild-type transthyretin; mTTR mutant-type transthyretin; NYHA New York Heart Association. Values are presented as medians with interquartile ranges (IQR), or as percentages. The strength of the associations was calculated with the nonparametric Mann-Whitney test or the chi-square test, as appropriate